Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara®...
Vaccine
Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025
LEXINGTON, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences...
Syensqo and Emulseo announce strategic partnership for advanced applications in the healthcare sector
Exploring new opportunities within the fast-growing market of microfluidics BORDEAUX, France, Feb. 20, 2025 /PRNewswire/ -- Syensqo, a leading specialty...
IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025
LAWRENCEVILLE, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its...
IO Biotech to Present at the 45th Annual Cowen Health Care Conference
Presentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted) NEW YORK, Feb....
Repligen Reports Fourth Quarter and Full Year 2024 Financial Results
Fourth quarter revenue of $168 million and full year revenue of $634 millionFourth quarter orders and revenues sequentially increased 11%...
PharmaJet to Highlight Benefits of Needle-free Intradermal Delivery at Medical Conference in Ethiopia
PharmaJet presentation will highlight the results of recent immunization studies using needle-free intradermal (ID) delivery for polio immunization campaigns. Data...
Investors Eye Biotech Sector as Cancer Therapy Market Surges
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 19, 2025 /PRNewswire/ -- USA News Group News...
Rapid Dose Therapeutics Corp Announces Proposed Equity Private Placement Financing
Burlington, Ontario--(Newsfile Corp. - February 18, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") today announced...
GC376, the Primary Component of Anivive’s Feline Infectious Peritonitis Drug, Nominated by AVMA and FelineVMA to FDA’s List of Bulk Drug Substance for Compounding Office Stock
Nomination could expedite GC376 availability for veterinariansBlack market FIP treatments shown to be unpredictable and dangerousOther organizations are encouraged to...
Foxx Life Sciences Successfully Hosted an Open House Event in Hyderabad
HYDERABAD, India, Feb. 17, 2025 /PRNewswire/ -- Foxx Life Sciences is delighted to announce the successful completion of its Open...
Emmes Group advances data security as ISMS certified ISO compliant
Gold-standard accreditation underscores Emmes Group's commitment to secure and data-rich trials for biotech and pharma partners ROCKVILLE, Md., Feb. 12,...
Terrain Biosciences emerges from stealth to enable faster therapeutics and vaccine development with better RNA
- Founded by Professors Omar Abudayyeh, Jonathan Gootenberg, and Patrick Hsu leveraging novel AI models and technologies for designing, building,...
Dalan Animal Health Unlocks the Power of Innate Immunity for a New Era in Disease Prevention
ATHENS, Ga., Feb. 12, 2025 /PRNewswire/ -- Dalan Animal Health, a global leader in bioscience innovation, today announced a major breakthrough...
Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Completed Phase 2 enrollment with randomization of 51 subjects into treatment and control armsPhase 1/2 study (N=60) demonstrated favorable safety...
17 Innovators to be Inducted as the National Inventors Hall of Fame Class of 2025
The Greatest Celebration of American Innovation will be held in Washington, D.C., on May 7-8 NORTH CANTON, Ohio, Feb. 11,...
IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer
Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology...
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and AstraZeneca’s FluMist® to address the recent avian influenza outbreaks
Planned Investigational New Drug application to expand on previous clinical work at the University of Alabama-Birmingham in which administration of...
Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash
Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the...
Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans
Despite the recently reported national decline in opioid overdose deaths, many U.S. communities, including New Orleans, continue to see an...